A retrospective study to compare uPr and UPCR to investigate the usefulness of UPCR measurement in patients undergoing molecular targeted therapy for renal cell carcinoma.
Latest Information Update: 25 Jul 2021
At a glance
- Drugs Axitinib (Primary) ; Everolimus (Primary) ; Nivolumab (Primary) ; Pazopanib (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 25 Jul 2021 New trial record